medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Ноя. 2, 2023
The
repeated
COVID-19
outbreaks,
despite
global
vaccination,
highlights
the
need
for
booster
doses.
Here,
we
present
outcomes,
up
until
day
90
post
of
a
randomized,
double-blind,
placebo-controlled
phase
1
clinical
trial
mRNA-based
vaccine
candidate;
COReNAPCIN
®
,
as
dose
in
adults
aged
18-50
who
had
previously
received
three
doses
inactivated
vaccines.
In
study,
30
participants
randomly
(2:2:1)
25
μg,
or
50
μg
placebo.
results
indicated
that
was
well
tolerated
vaccinated
individuals
both
groups
with
no
life-threatening
other
serious
adverse
events.
most
noticeable
solicited
events
were
pain
at
site
injection,
fatigue
and
myalgia.
Regarding
immunogenicity,
given
seroprevalence
SARS-CoV-2
antibodies
due
to
vaccination
history
all,
previous
infection
some
participants,
recipients
two
weeks
showed
significant
fold
increases
level
anti-RBD
(6.6
8.1
folds)
anti-spike
(11.5
21.7
folds),
potent
neutralizing
(10.2
8.4
groups,
respectively,
while
meaningful
changes
observed
placebo
group.
Additionally,
increase
spike-specific
IFN-γ
T-cell
response
upon
underscores
activation
cellular
immunity.
Altogether,
favorable
safety,
tolerability,
immunogenicity
profile
support
its
further
development.
Trial
registration
number
IRCT20230131057293N1
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Фев. 21, 2024
Abstract
Background
Over
a
dozen
vaccines
are
in
or
have
completed
phase
III
trials
at
an
unprecedented
speed
since
the
World
Health
Organization
(WHO)
declared
COVID-19
pandemic.
In
this
review,
we
aimed
to
compare
and
rank
these
indirectly
terms
of
efficacy
safety
using
network
meta-analysis.
Methods
We
searched
Embase,
MEDLINE,
Cochrane
Library
for
randomized
controlled
(RCTs)
from
their
inception
September
30,
2023.
Two
investigators
independently
selected
articles,
extracted
data,
assessed
risk
bias.
Outcomes
included
preventing
symptomatic
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
incidence
serious
adverse
events
(SAEs)
according
vaccine
type
individual
adults
elderly
individuals.
The
ratio
mean
differences
were
calculated
with
95%
confidence
intervals
Bayesian
Results
A
total
25
RCTs
involving
22
study.
None
had
higher
SAEs
than
placebo.
Inactivated
virus
might
be
safest,
surface
under
cumulative
ranking
curve
(SUCRA)
value
0.16.
BIV1-CovIran
showed
highest
index
(SUCRA
value:
0.13),
followed
by
BBV152,
Soberana,
Gam-COVID-Vac,
ZF2001.
There
no
significant
among
various
types
regarding
SARS-CoV-2
infection,
although
there
was
trend
toward
mRNA
0.09).
BNT162b2
0.02)
vaccines,
mRNA-1273,
Abdala,
NVX-CoV2373.
0.08)
population,
whereas
CVnCoV,
CoVLP
+
AS03,
CoronaVac
not
significantly
different
Conclusions
superior
efficacy,
while
inferior
other
types.
elderly,
lowest
adults.
Viruses,
Год журнала:
2024,
Номер
16(2), С. 203 - 203
Опубликована: Янв. 29, 2024
Vaccine
development
against
SARS-CoV-2
has
been
highly
successful
in
slowing
down
the
COVID-19
pandemic.
A
wide
spectrum
of
approaches
including
vaccines
based
on
whole
viruses,
protein
subunits
and
peptides,
viral
vectors,
nucleic
acids
developed
parallel.
For
all
types
vaccines,
good
safety
efficacy
have
obtained
both
preclinical
animal
studies
clinical
trials
humans.
Moreover,
emergency
use
authorization
granted
for
major
vaccines.
Although
high
demonstrated,
rare
cases
severe
adverse
events
detected
after
global
mass
vaccinations.
Emerging
variants
possessing
enhanced
infectivity
affected
vaccine
protection
requiring
re-design
re-engineering
novel
candidates.
Furthermore,
insight
is
given
into
preparedness
emerging
variants.
Pathogens and Disease,
Год журнала:
2023,
Номер
81
Опубликована: Янв. 1, 2023
Abstract
Early
reports
on
coronavirus
disease
2019
(COVID-19)
vaccines
presented
the
short-term
adverse
events
(AEs).
This
follow-up
study
investigated
a
standard
regimen
based
protein
subunit
vaccines,
PastoCovac
and
Plus,
combinational
vaccine
regimens
including
AstraZeneca/PastoCovac
Plus
Sinopharm/PastoCovac
Plus.
The
participants
were
followed
up
to
6
months
post
booster
shot.
All
AEs
collected
through
in-depth
interviews
using
valid
researcher-made
questionnaire
evaluated
regarding
association
with
vaccines.
Of
509
individuals,
6.2%
of
had
late
AEs,
whom
3.3%
suffered
from
cutaneous
manifestations,
by
1.1%
arthralgia
complaints,
neurologic
disorders,
0.3%
ocular
problems
metabolic
complications,
no
significant
difference
between
regimens.
For
regimen,
2%
individuals
experienced
as
(1%),
neurological
disorders
(0.3%),
(0.3%)
involvement
joints
(0.3%).
Notably,
75%
persistent
end
study.
A
low
number
captured
in
18
12
improbable,
5
unclassifiable,
4
possible
3
probable
associated
benefits
COVID-19
vaccination
far
exceed
potential
risks
seem
be
uncommon.
Heliyon,
Год журнала:
2023,
Номер
9(10), С. e20555 - e20555
Опубликована: Сен. 29, 2023
COVID-19
pandemic
has
been
managed
through
global
vaccination
programs.
However,
the
antibody
waning
in
various
types
of
vaccines
came
to
notice.
Hereby,
PastoCovac
Plus
as
a
protein
subunit
vaccine
was
investigated
immunized
health
care
workers
by
COVAXIN
(BBV152).
The
booster
recommended
at
least
three
months
post
second
dose
COVAXIN.
Sera
collection
done
before
and
after
each
injection.
SARS-CoV-2
PCR
test
monthly
detect
any
asymptomatic
symptomatic
breakthrough.
47.9
24.3%
participants
were
seronegative
for
anti-N
anti-S
antibodies
COVAXIN,
respectively.
On
average,
fold-rises
70,
93,
8
mean-rises
23.32,
892.4,
5.59
recorded
regarding
neutralizing
antibody,
quantitative
semi-quantitative
anti-Spike
Anti-Spike
seroconversion
seen
59.3%
45.7%,
breakthrough
assessment
showed
that
all
isolated
samples
belonged
Delta
variant.
boosting
is
strongly
combination
with
inactivated
platforms
against
SARS-CoV-2.
PLoS Pathogens,
Год журнала:
2023,
Номер
19(11), С. e1011744 - e1011744
Опубликована: Ноя. 1, 2023
Background
This
study
aimed
at
evaluation
and
comparison
of
PastoCovac
Plus
protein-subunit
vaccine
in
parallel
with
ChAdOx1-S
(AstraZeneca)
BBIBP-CorV
(Sinopharm)
primarily
vaccinated
volunteers
two
doses
or
BBIBP-CorV.
Materials
methods
194
enrolled
the
who
were
previously
primed
2
vaccines.
They
divided
into
heterologous
regimens
receiving
a
third
dose
Plus,
homologous
groups
ChAdOx1-S.
Serum
samples
obtained
just
before
4
weeks
after
booster
dose.
Anti-spike
IgG
neutralizing
antibodies
quantified
conventional
live-virus
neutralization
titer,
(cVNT50)
assay
was
done
against
Omicron
BA.5
variant.
Moreover,
adverse
events
data
recorded
doses.
Results
ChAdOx1-S/PastoCovac
group
reached
73.0
units
increase
anti-Spike
rise
compared
to
ChAdOx1-S/
(
P
:
0.016).
No
significant
difference
observed
between
regarding
antibody
0.256),
indicating
equivalency
both
types.
Adjusting
for
baseline
titers,
BBIBP-CorV/PastoCovac
showed
135.2
<0.0001)
IgG,
3.1
0.008)
unit
mean
group.
Adjustment
COVID-19
history,
age,
underlying
diseases,
titers
increased
odds
fourfold
(OR:
1.9;
0.199)
BBIBP
CorV
37.3;
<
0.0001)
their
corresponding
arms.
The
rise,
adjustment
same
variables,
2.4
0.610)
5.4
0.286)
groups.
All
types
had
potency
neutralize
variant
no
difference.
highest
rate
event
incidence
Conclusions
application
individuals
successfully
specific
antibodies’
levels
without
any
serious
events.
could
be
administrated
regimen
effectively
boost
humoral
immune
responses.
Health and Ecology Issues,
Год журнала:
2025,
Номер
21(4), С. 26 - 36
Опубликована: Янв. 16, 2025
Objective
.
To
assess
the
efficacy
of
immunogenicity
Soberana
Plus
(FINLAY-FR-1A)
vaccine
in
adults
previously
vaccinated
against
COVID-19.
Materials
and
methods
A
total
98
participants
participated
study.
The
was
studied
by
measuring
IgG
concentration
to
SARS-CoV-2
enzyme-linked
immunosorbent
assay
(ELISA)
at
4
study
sites:
day
0,
42
days,
90
days
180
after
administration.
Results
Participants
were
divided
into
groups
based
on
their
primary
immunization:
1)
Sputnik
V
(Gam-COVID-Vac)
/
Light;
2)
Sinopharm
(BBIBP-CorV);
3)
(BBIBP-CorV)
+
(Gam-COVIDVac)
Light.
highest
level
observed
administration
booster
dose
(p<
0,001).
At
“90
day”
point,
levels
higher
with
Light
(BBIBP-CorV),
however,
this
group
had
before
In
vaccination,
age
“45
plus”
level,
compared
“25-45
years
old”
(р=0,048).
Conclusion
is
quite
immunogenic.
marked
(р
International Journal of Preventive Medicine,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 1, 2025
Abstract
Background:
Understanding
the
seasonal
and
spatial
patterns
of
COVID-19
hospitalization
deaths
is
crucial
for
effective
hospital
management,
resource
allocation,
public
health
interventions.
The
current
study
conducts
a
spatiotemporal
hotspot
analysis
that
explores
geographical
high-risk
areas
hospitalizations
in
Iran.
Methods:
Provincial-level
data
on
laboratory-confirmed
cases
with
acute
respiratory
symptoms
Iran
(February
2019–March
30,
2022)
were
collected.
Hotspot
analyses
mapped
incidence
risks,
Global
Moran’s
autocorrelation
identified
clusters.
Results:
Over
2
years,
26
hotspots
11
cold
spots
(
P
<
0.05).
Western
central
provinces
showed
highest
hotspots,
while
west
north
had
most
death
hotspots.
South
southeast
exhibited
low
number
spots.
High-risk
prevalent
spring
autumn,
mainly
west,
north,
regions.
Conclusions:
This
research
unveils
clustering
fatalities
during
severe
pandemic.
Spatial
clusters
dynamic
varied
across
regions
time.
Prioritizing
critical
epidemic
waves,
devising
care
strategies,
implementing
preventive
measures
can
significantly
improve
outcomes.
Vaccine
development
against
SARS-CoV-2
has
been
highly
successful
in
slowing
down
the
COVID-19
pandemic.
A
wide
spectrum
of
approaches
including
vaccines
based
on
whole
viruses,
protein
subunits
and
peptides,
viral
vectors,
nucleic
acids
have
developed
parallel.
For
all
types
vaccines,
good
safety
efficacy
obtained
both
preclinical
animal
studies
clinical
trials
humans.
Moreover,
emergency
use
authorization
granted
for
vaccines.
Although
high
demonstrated,
rare
cases
severe
adverse
events
detected
after
global
mass
vaccinations.
Emerging
variants
possessing
enhanced
infectivity
affected
vaccine
protection
requiring
re-design
re-engineering
novel
candidates.
Furthermore,
insight
into
preparedness
emerging
other
future
infections
is
given.
